Ropinirole is used to treat Parkinson’s disease and restless legs syndrome.
Immediate-release tablets are taken three times daily for Parkinson’s and once daily at bedtime for restless legs syndrome.
Extended-release tablets are only for Parkinson’s and are taken once daily.
Doses can be taken with or without food.
Avoid alcohol. Ropinirole should never be taken by people who drink too much alcohol.
Ropinirole is a generic prescription drug that treats Parkinson’s disease and restless legs syndrome (RLS). It belongs to a family of drugs called dopamine agonists, that is, drugs that act like dopamine, a chemical that transmits signals between nerves. The symptoms of both Parkinson’s and RLS are related to low dopamine levels, so ropinirole activates dopamine receptors in place of dopamine. Dosages will depend on the formulation. Immediate-release tablets are taken three times daily while extended-release tablets are only taken once per day.
People can take one of two ropinirole dosage forms: immediate-release or extended-release tablets. Extended-release tablets only treat Parkinson’s disease.
Immediate-release tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg
Extended-release tablets: 2 mg, 4 mg, 6 mg, 8 mg, 12 mg
The Food and Drug Administration (FDA) has approved ropinirole to treat Parkinson’s disease and restless legs syndrome. The symptoms of both conditions are related to low dopamine levels. As a dopamine agonist, ropinirole acts like dopamine in the nervous system. In treating these conditions, physicians prescribe ropinirole as a day-long treatment for Parkinson’s but only prescribe ropinirole for bedtime use in people with RLS.
Not everyone can safely take ropinirole. Contraindications include alcohol abuse, liver failure, or known allergies to ropinirole.
Check our best Ropinirole prices
Ropinirole dosage chart |
|||
|---|---|---|---|
| Indication | Starting dosage | Standard dosage | Maximum dosage |
| Parkinson’s disease | 0.25 mg immediate-release tablet taken 3 times daily for 1 week | 0.25–8 mg immediate-release tablets taken 3 times daily OR 2–24 mg extended-release tablets taken once daily | 24 mg daily |
| Restless legs syndrome | 0.25 mg immediate-release tablet taken once daily 1–3 hours before bedtime | 0.25–4 mg immediate-release tablets taken once daily 1–3 hours before bedtime | 4 mg daily |
Parkinson’s disease progressively reduces the brain’s production of dopamine. This chemical is an essential neurotransmitter that transmits signals from one nerve to another. It is vital for controlling muscle movement, mood, blood pressure, and the function of many of the body’s organs. When the disease starts, the first signs are usually problems with muscles and movement including slow movements, muscle stiffness, and tremor. People with Parkinson’s have other problems as well: heartbeat changes, blood pressure changes, depression, and hallucinations.
To treat movement problems, the first-line therapy is to use dopamine in the form of levodopa or carbidopa. First-line treatment includes drugs like ropinirole and pramipexole. Although they aren’t exactly dopamine, their mechanism of action in the nervous system is nearly identical to dopamine. They’re either added to levodopa/carbidopa therapy or used on their own for both early and advanced Parkinson’s disease.
For Parkinson’s, doses of ropinirole begin very small. The clinicians gradually increase the dose week after week until the most effective dose is reached. This titration process can take anywhere from a month to almost three months. Prescribers start with immediate-release ropinirole taken three times daily. At any time, the healthcare provider may switch to extended-release ropinirole for easier dosing.
Standard adult dosage for Parkinson’s disease: 0.25–8 mg immediate-release tablets taken three times daily OR 2–24 mg extended-release tablets taken once daily
Maximum adult dosage for Parkinson’s disease: 24 mg per day
Restless legs syndrome causes a strong urge to move the legs often accompanied by uncomfortable sensations or pain if the leg isn’t moved. Symptoms worsen when the legs are at rest and get better with activity. Symptoms are at their worst at night because dopamine levels significantly decrease after we fall asleep.
Ropinirole acts like dopamine in the central nervous system. When an immediate-release ropinirole tablet is taken before bedtime, people get significant relief from the RLS symptoms at night. Although ropinirole is FDA approved to treat RLS, the American Academy of Sleep Medicine (AASM) recommends its use in people with moderate to severe RLS.
Standard adult dosage for restless legs syndrome: 0.25–4 mg immediate-release tablets taken once daily 1–3 hours before bedtime
Maximum adult dosage for restless legs syndrome: 4 mg daily
The FDA has not approved ropinirole for use in pediatric patients.
Dose reductions are reserved only for people with the most severe liver or kidney problems or who are on dialysis. Most other people don’t require dose adjustments.
Patients with renal impairment (kidney disease):
Mild to moderate renal impairment (creatinine clearance 30–89 mL/min): No dosage adjustment required
Severe renal impairment (end-stage renal disease): Initial dose of 0.25 mg once daily
Hemodialysis: Initial dose of 0.25 mg once daily
Patients with hepatic impairment (liver disease): Initial doses are increased cautiously
Patients with liver failure: Use with caution
Veterinarians use ropinirole eye drops in dogs to induce vomiting. Only veterinary professionals give this medicine. Anywhere from one drop to eight drops are used depending on the dog’s body weight. The dog usually begins to throw up about 10 minutes after the dose is administered.
Ropinirole tablets are easy to take but involve some special considerations. Most importantly, do not stop taking doses until speaking with the prescriber. You may experience serious withdrawal symptoms. If you do stop taking ropinirole, do not start again until talking to the prescriber. You may need to restart at the lowest possible dose.
Take this medication as directed.
Doses will change in the first few weeks or months of treatment.
Do not change the dose yourself. If treatment does not seem to be working, talk to the prescriber.
Please read the Patient Information sheet included with the medicine.
Take ropinirole tablets with or without food.
If the tablets bring on nausea, try taking ropinirole doses with food.
Take immediate-release tablets three times daily.
If prescribed for restless legs syndrome, take the immediate-release dose before bedtime.
Take extended-release tablets once daily.
Swallow the extended-release tablet whole without chewing, crushing, or breaking it.
Store ropinirole tablets at room temperature protected from moisture and light.
For Parkinson’s disease, the total daily target dose is the same whether people take immediate-release or extended-release ropinirole. The only difference involves how many times doses are taken each day.
However, everyone will start therapy with immediate-release ropinirole at a low dose (0.25 mg three times daily). People are switched to extended-release only if they are currently taking immediate-release ropinirole.
People with restless legs syndrome are not prescribed extended-release ropinirole.
For both Parkinson’s disease and restless legs syndrome, it takes several weeks of steadily increasing doses to reach an effective dose, sometimes as long as 10 weeks. In clinical trials, participants taking ropinirole experienced symptom improvement in the first 12 weeks.
With a half-life of six hours, ropinirole is usually cleared from the system in a little over a day.
Ask the prescriber what to do if a ropinirole dose is missed. Do not double the next dose to make up for the missed dose.
Ropinirole is a long-term treatment that can last for months, years, or even a lifetime. While there are no side effects specifically caused by long-term use, ropinirole does have serious side effects. The drug may need to be discontinued or the dose reduced if any of these side effects are experienced.
Do not stop taking ropinirole without first talking to the prescribing healthcare provider. The abrupt discontinuation of ropinirole can bring on withdrawal symptoms such as depression, anxiety, fatigue, trouble sleeping, sweating, pain, muscle stiffness, fever, and confusion. To avoid these problems, the prescriber will gradually reduce the dose over several weeks.
Although ropinirole is intended for long-term use, the prescriber may need to stop treatment if there are problems such as allergic reactions or severe side effects. The clinician may choose to use another dopamine agonist for Parkinson’s and restless leg syndrome.
The maximum total daily dose of ropinirole is 24 mg daily. For restless legs syndrome, the maximum dose is 4 mg daily. Higher doses are not effective.
Immediately contact a poison helpline or go to an emergency room if too much ropinirole is taken. A ropinirole overdose can be fatal.
Symptoms of an overdose include nausea, vomiting, dizziness, excessive sweating, involuntary movements, hallucinations, palpitations, coughing, chest pain, feeling weak, fatigue, fainting, nightmares, claustrophobia, and confusion.
To avoid possible drug interactions, tell the prescribing clinician about all the prescription drugs, over-the-counter medications, and supplements being taken, particularly:
Antipsychotic medications or other dopamine inhibitors (dopamine antagonists) like metoclopramide
Smoking can make ropinirole less effective, so get medical advice from the prescriber if you’re a smoker.
Avoid alcohol when taking ropinirole; the combination could be deadly. Patients taking ropinirole should avoid alcohol consumption and inform their healthcare provider about any alcohol use.
Ask the prescriber for medical advice if you get pregnant. Ropinirole can cause birth defects in animals but its effects on human pregnancy haven’t been studied.
Although it hasn’t been studied in breastfeeding mothers, ropinirole theoretically could interfere with lactation. Women who are nursing a preterm or newborn infant may consider other treatment options.
The most common side effects of ropinirole are nausea, vomiting, drowsiness, somnolence, dizziness, feeling weak, feeling faint (syncope), abdominal pain, and dizziness.
The FDA advises healthcare professionals to explain all the risks of ropinirole before treatment begins. Patients should be aware of possible adverse reactions and call the prescriber if any of the symptoms of an adverse effect are experienced.
People taking ropinirole may experience serious problems such as:
Falling asleep or sudden daytime sleepiness while doing normal activities of daily living
Passing out or feeling faint, especially when standing up (orthostatic hypotension)
Involuntary movements (dyskinesia)
Psychotic symptoms, including hallucinations, delusions, paranoia, confusion, and disorganized thinking
Loss of impulse control, unusual urges, or compulsive behaviors like gambling, sex, binge eating, or spending money
Low blood pressure
Slow or fast heart rate
Allergic reactions
The symptoms of restless leg syndrome may get worse when ropinirole therapy is first started.
Clevor ropinirole hydrochloride solution animal drug information, DailyMed (NIH National Library of Medicine)
Requip XL drug summary, Prescriber’s Digital Reference (PDR)
Ropinirole, StatPearls
Ropinirole tablet prescribing information, DailyMed (NIH National Library of Medicine)
Ropinirole extended-release tablet prescribing information, DailyMed (NIH National Library of Medicine)
The treatment of restless legs syndrome and periodic limb movement disorder in adults, Sleep
Abhijeet Danve grew up in India and moved to the United States in 2009. He is an Associate Professor of Medicine at Yale University, New Haven, Connecticut. He completed Medical School and Internal Medicine Residency at Seth G S Medical College and King Edward Memorial Hospital, Mumbai, India. Dr. Danve then went on to complete his clinical rheumatology fellowship at Oregon Health and Science University, Portland, and a research fellowship at the University of Nebraska Medical Center, Omaha. Dr. Danve is a recipient of the Marshall J. Schiff Memorial Research Award (2013) and Distinguished Fellow Award (2015) awarded by the American College of Rheumatology and the Jane Bruckel Early Career Award by the Spondylitis Association of America (2019). Dr. Danve has a particular interest in patient care and research in the field of spondyloarthritis and gout. Dr. Danve’s work focuses on the early identification and diagnosis of axial spondyloarthritis and improving the management of gout patients worldwide. He has authored many peer reviewed publications, editorials, and expert opinion letters in reputed journals and has appeared on TV interviews as well as webinars. He lives in Glastonbury, Connecticut, with his wife, Supriya, and two boys.
...Health education, drug info, wellness & more
Prescription savings vary by prescription and by pharmacy, and may reach up to 80% off cash price. This is a medical discount plan. This is NOT insurance. This program offers you the opportunity to locate providers of various types of medical services who will offer their services to you at discounted rates. The range of discounts for medical or ancillary services provided under the plan will vary depending on the type of provider and service received. You are fully responsible for paying for all health care services but will be entitled to receive a discount from those health care providers in accordance with the specific pre-negotiated discounted fee schedule. This program does not guarantee the quality of the services or procedures offered by the providers. Except for prescription drugs which you will pay directly to the pharmacy at the time of purchase, all other services received through a program provider will be charged to the credit card on file in your member account. The charge will include an administrative fee for use of the program. Towers Administrators LLC is the licensed discount medical plan organization with its administrative office located at 4510 Cox Road, Suite 111, Glen Allen, VA 23060. SingleCare Services, LLC is the marketer of the discount medical plan organization including its website, singlecare.com, with its corporate office located at 99 High Street, Suite 2800, Boston, MA 02110. For additional information, including an up-to-date list of providers, or assistance with any issue related to program membership, please contact member support any time at www.singlecare.com, or by calling toll-free 844-234-3057, 24 hours, 7 days a week (except major holidays). Pharmacy names, logos, brands, and other trademarks are the property of their respective owners.
Blog articles are not medical advice. They are intended for general informational purposes and are not meant to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. If you think you may have a medical emergency, immediately call your physician or dial 911.
© 2025 SingleCare Administrators. All rights reserved
© 2025 SingleCare Administrators. All rights reserved